Oropharyngeal carcinoma: A single institution study of 338 primaries with special reference to high-risk human papillomavirus-mediated carcinoma with aggressive behavior.
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Carcinoma, Squamous Cell
/ chemistry
Cell Nucleus
/ pathology
Cyclin-Dependent Kinase Inhibitor p16
/ analysis
Disease Progression
Female
Humans
Illinois
Male
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Oropharyngeal Neoplasms
/ chemistry
Papillomaviridae
/ pathogenicity
Papillomavirus Infections
/ mortality
Progression-Free Survival
Registries
Retrospective Studies
Tumor Burden
Aggressive behavior
Human papillomavirus
Oropharynx
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
08
2020
revised:
02
10
2020
accepted:
04
10
2020
pubmed:
29
10
2020
medline:
29
9
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
In a retrospective review, we identified 332 patients with 338 pathologically diagnosed primary oropharyngeal carcinomas (OPC) between January 2013 and March 2020 with known p16/HPV status from a tumor registry at Northwestern Memorial Hospital. The tumors predominantly involved the palatine tonsil (51 %) and the base of the tongue/lingual tonsil (38 %). The most common type of cancer was non-keratinizing squamous cell carcinoma (60 %), and the majority of primaries were p16 positive/HPV-mediated (86 %). A cohort of p16 positive/HPV mediated OPC (27/283, 9.5 %) presented with aggressive clinical behavior, including multiple distant metastases at unusual sites. Tumor size >2 cm and the presence of tumor anaplasia/multinucleation were significantly associated with an increased rate of distant metastases in p16 positive/HPV mediated cases, both in unadjusted and adjusted analyses (all P < 0.05). Of the 332 individuals in the overall cohort, 38 individuals died due to their disease within the observed follow-up time. Among the 283 patients with p16 positive/HPV mediated tumors, survival was estimated at 97 % (95 % CI 95 %, 100 %) at 1 year, 95 % (95 % CI 92 %, 98 %) at 2 years, and 80 % (95 % CI 72 %, 89 %) at 5 years. The presence of tumor anaplasia/multinucleation and distant metastasis were both significantly associated with poorer disease-specific survival in p16 positive/HPV mediated cases (both P < 0.05), with the survival effect of tumor anaplasia/multinucleation likely mediated in part through its association with distant metastasis. For p16 positive/HPV-mediated OPC, age, smoking status, tumor status, and lymph node status were not significantly associated with disease-specific survival in our study.
Identifiants
pubmed: 33113454
pii: S0344-0338(20)32098-7
doi: 10.1016/j.prp.2020.153243
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153243Informations de copyright
Copyright © 2020 Elsevier GmbH. All rights reserved.